U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Drugs
  3. News & Events for Human Drugs
  4. Advancing Treatments for Post-Traumatic Stress Disorder (PTSD) - 09/06/2024
  1. News & Events for Human Drugs

Meeting | Mixed

Event Title
Advancing Treatments for Post-Traumatic Stress Disorder (PTSD)
September 6, 2024

Date:
September 6, 2024
Time:
1:00 PM - 3:30 PM ET

Attend the public meeting:
Registration through Reagan-Udall Foundation

The U.S. Food and Drug Administration (FDA), in partnership with the Reagan-Udall Foundation for the FDA, is hosting a hybrid public meeting, “Advancing Treatments for Post-Traumatic Stress Disorder (PTSD),” in support of FDA’s ongoing focus on understanding medical need for PTSD treatment with the goal of facilitating treatment development.

This public meeting, with both virtual and in-person attendance options, will feature a panel discussion with federal partners to explore efforts to accelerate treatment development for PTSD, including psychedelic drug development. This meeting will also provide an opportunity for people with lived PTSD experience, including veterans, family members, and patient advocates; researchers and scientists; and drug developers to provide public comment.

Thirty stakeholders will have up to three minutes each to present public comment either virtually or in-person. The deadline to request to present stakeholder comment is 12 PM (ET) on September 3, 2024. Speakers will be notified by September 4.

If you have questions or prefer to submit written comments, please submit questions and up to two pages of comments to PTSD@reaganudall.org. Written comments will be accepted through September 20, 2024.

Back to Top